Advances in inflammatory bowel diseases in children

Minerva Pediatrica

Volumn 64, Issue 3, 2012, Pages 257-270

  Michail, S ^a,b   Ramsy, M ^a   Soliman, E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Child; Colitis, ulcerative; Crohn disease

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIBODY; AZATHIOPRINE; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; BUDESONIDE; CALGRANULIN; CORTICOSTEROID; FLAGELLIN; IMMUNOMODULATING AGENT; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN; PLACEBO; PROBIOTIC AGENT; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ANTIBODY;

ABDOMINAL PAIN; ACNE; ANTIBODY PRODUCTION; ANUS FISTULA; AUTOIMMUNITY; BIOLOGICAL THERAPY; BLOOD LEVEL; BONE MARROW SUPPRESSION; BONE NECROSIS; CANCER RISK; CHILD; CHILD HEALTH CARE; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; CLOSTRIDIUM; COLON RESECTION; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; CROHN DISEASE; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC FEEDING; ENTERITIS; ENZYME ACTIVITY; FACE EDEMA; FECES ANALYSIS; FIRMICUTES; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TRACT EXAMINATION; GENETIC POLYMORPHISM; GROWTH DISORDER; HEADACHE; HISTOPLASMOSIS; HUMAN; HYPERTENSION; INTESTINE FLORA; INTESTINE MUCOSA; LABORATORY TEST; LACTOBACILLUS; LIVER TOXICITY; LUNG ALVEOLITIS; MAGNETIC RESONANCE ENTEROGRAPHY; MEDICAL SPECIALIST; META ANALYSIS (TOPIC); MICROBIOME; MOOD CHANGE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPPORTUNISTIC INFECTION; OSTEOPENIA; PANCREATITIS; PATIENT MONITORING; PEDIATRICIAN; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIDE EFFECT; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; ULCERATIVE COLITIS; VOMITING;

ANTI-INFLAMMATORY AGENTS; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC; PROBIOTICS; TREATMENT OUTCOME;

EID: 84862509033     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Benchimol EI, Guttmann A, To T, Rabeneck L, Griffiths AM. Changes to surgical and hospitalization rates of pediatric inflammatory bowel disease in Ontario, Canada (1994-2007). Inflamm Bowel Dis 2011;17:2153-61.
2. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361):2033-45.
3. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21.
4. Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in UCand features that distinguish it from Crohn disease. Am J Clin Pathol 2006;126:365-76.
5. Dendrinos K, Cerda S, Farraye FA. The "cecal patch" in patients with ulcerative colitis. Gastrointest Endosc 2008;68:1006-7; discussion 1007.
6. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez- Humarán LG, Gratadoux JJ et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-6.
7. Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's disease and UCcan be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008;14:147-61.
8. Michail S, Durbin M, Turner D, Griffiths AM, Mack DR, Hyams J et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis 2011 [Epub ahead of print].
9. Henderson P, Casey A, Lawrence SJ, Kennedy NA, Kingstone K, Rogers P et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol Am J Gastroenterol 2012 [Epunb ahead of print].
10. Kolho KL, Turner D, Veereman-Wauters G, Sladek M, de Ridder L, Shaoul et al. Rapid test for fecal calprotectin levels in children with Crohn's disease. J Pediatr Gastroenterol Nutr 2012 [Epub ahead of print].
11. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012 [Epub ahead of print].
12. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transi Res 2011;159:313-25.
13. Sauer CG, Kugathasan S, Martin DR, Applegate KE. Medical radiation exposure in children with inflammatory bowel disease estimates high cumulative doses. Inflamm Bowel Dis 2011;17:2326-32.
14. Jaffe TA, Gaca AM, Delaney S, Yoshizumi TT, Toncheva G, Nguyen G et al. Radiation doses from small-bowel follow-through and abdominopelvic MDCT in Crohn's disease. AJR Am J Roentgenol 2007;189:1015-22.
15. Patel P, Ormanoski M, Hoadley KM. Magnetic resonance enterography findings in Crohn's disease in the pediatric population and correlation with fluoroscopic and multidetector computed tomographic techniques. J Clin Imaging Sci 2011;1:41.
16. Levine A, Kori M, Dinari G, Broide E, Shaoul R, Yerushalmi B et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009;15:1055-61.
17. Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schütz T et al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr 2006;25:260-74.
18. Working Group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition, Konno M, Kobayashi A, Tomomasa T, Kaneko H, Toyoda S, Nakazato Y et al. Guidelines for the treatment of Crohn's disease in children. Pediatr Int 2006;48:349-52.
19. Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H; on Behalf of the IBD Working Group of the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition. Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010 [Epub ahead of print].
20. Critch J, Day AS, Otley A, King-Moore C, Teitelbaum JE, Shashidhar H; NASPGHAN IBD Committee.Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012;54:298-305.
21. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53.
22. Day AS, Whitten KE, Sidler M, Lemberg DA et al. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther 2008;27:293-307.
23. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007:CD000542.
24. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
25. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002;359:1541-9.
26. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
27. Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73; quiz 1165-6.
28. Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-7.
29. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33; quiz 591.
30. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, Macintosh DG et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
31. Rosh JR, Lerer T, Markowitz J, Goli SR, Mamuia P, Noe JD et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9.
32. Hyams J, Griffiths A, Markowitz J. Induction and Maintenance Adalimumab for Moderate to Severe Crohn's Disease in Children. Gastroenterology 2011;140:S90.
33. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104:1293-301.
34. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005:CD003715.
35. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
36. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009:CD000545.
37. Feagan, B.G., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
38. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
39. Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cézard JP et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006;12:1053-7.
40. Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007;102:2804-12; quiz 2803, 2813.
41. Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A et al. The natural history of corticosteroid therapy for UCin children. Clin Gastroenterol Hepatol 2006;4:1118-23.
42. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75; quiz 432-3.
43. Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:841-55.
44. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006:CD005112.
45. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
46. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J et al. Colectomy rate comparison after treatment of UCwith placebo or infliximab. Gastroenterology 2009;137:1250-60; quiz 1520.
47. Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:391-399 e1.
48. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006:CD000543.
49. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N et al. Clin Gastroenterol Hepatol 2009;7:762-9.
50. Hyams JS, Lerer T, Mack D, Bousvaros A, Griffiths A, Rosh J et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011;106:981-7.
51. Tschudy J, Michail S. Disseminated histoplasmosis and Pneumocystis pneumonia in a child with Crohn disease receiving infliximab. J Pediatr Gastroenterol Nutr2011;51:221-2.
52. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81.
53. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005;11:833-9.
54. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006:CD004826.
55. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008;53:2524-31.
56. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007:CD005573.
57. Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol 2010;16:1908-15.
58. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43.
59. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008;53:1278-84.
60. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouchanal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010:CD001176.